A possible association between congenital abnormalities and the use of different sulfonamides during pregnancy
Foundation for the Community Control of Hereditary Diseases, Budapest, Hungary. Congenital Anomalies
(Impact Factor: 1.08).
07/2004; 44(2):79-86. DOI: 10.1111/j.1741-4520.2004.00012.x
ABSTRACT The objective of the study presented here was to check the debated human teratogenic potential of sulfonamide drugs. Five different sulfonamides such as sulfamethazine, sulfathiourea, sulfamethoxypyridazine, sulfamethoxydiazine and the combination of sulfamethazine-sulfathiourea-sulfamethoxypyridazine were differentiated.
Cases with congenital abnormalities were compared with their matched controls without congenital abnormalities in the population-based large data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996.
Of 38 151 newborn infants without any congenital abnormalities (control group), 163 (0.4%) had mothers who were treated with the sulfonamides studied during pregnancy, while of 22 843 cases with congenital abnormalities, 140 (0.6%) had mothers who were treated with the sulfonamides studied during pregnancy. The analysis of cases and matched controls indicated a higher rate of cardiovascular malformation (adjusted prevalence odds ratios [POR] with 95% CI: 3.5, 1.9–6.4) and clubfoot (adjusted POR with 95% CI: 2.6, 1.1–6.2) in infants born to mothers with sulfonamide treatment in the second and third months of pregnancy. The detailed analysis of different sulfonamides showed a possible association between cardiovascular malformations (adjusted POR with 95%; CI: 6.5, 2.6–15.9), particularly ventricular septal defect (17.1, 1.3–141.1) and sulfamethoxydiazine during the second and third months of pregnancy. In addition, a possible association was found between clubfoot and sulfathiourea, both during the entire pregnancy (adjusted POR with 95% CI: 2.3, 1.2–4.3) and in the second and third months of gestation (3.9, 1.1–13.8).
Thus, maternal treatment of sulfamethoxydiazine may cause ventricular septal defect, while sulfathiourea may induce clubfoot; however, further studies are needed to verify or reject these associations.
Available from: Robert Brian Lowry
- "As we mentioned previously within the group of tetracyclines, oxytetracylines 23 were teratogenic while doxycyclines 24 were not teratogenic. At the evaluation of seven orally used sulfonamides, only two showed teratogenic potential, and they induced different CAs 30. "
[Show abstract] [Hide abstract]
ABSTRACT: Environmental teratogenic factors (e.g. alcohol) are preventable. We focus our analysis on human teratogenic drugs which are not used frequently during pregnancy. The previous human teratogenic studies had serious methodological problems, e.g. the first trimester concept is outdated because environmental teratogens cannot induce congenital abnormalities in the first month of gestation. In addition, teratogens usually cause specific congenital abnormalities or syndromes. Finally, the importance of chemical structures, administrative routes and reasons for treatment at the evaluation of medicinal products was not considered. On the other hand, in the so-called case-control epidemiological studies in general recall bias was not limited. These biases explain that the teratogenic risk of drugs is exaggerated, while the benefit of medicine use during pregnancy is underestimated. Thus, a better balance is needed between the risk and benefit of drug treatments during pregnancy. Of course, we have to do our best to reduce the risk of teratogenic drugs as much as possible, however, it is worth stressing the preventive effect of drugs for maternal diseases (e.g. diabetes mellitus and hyperthermia) related congenital abnormalities.
International journal of medical sciences 02/2005; 2(3):100-6. · 2.00 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: The objectives of this paper are to describe the Hungarian case-control surveillance system of congenital abnormalities (HCCSCA), to summarize the principles of this activity and our main experiences. Among the main principles, the importance of the time factor (the first trimester concept is outdated), the differentiation of isolated and multiple manifestations of the seemingly same congenital abnormalities, noxa specificity, the separation of drugs and pregnancy supplements within medicinal products (or medicines) are stressed. After some methodological problems (recall bias, chance effect), the main experiences regarding the risk and benefit of medicines are summarized. The conclusion is that the results of our studies based on the data set of the HCCSCA showed that at present the exaggerated teratogenic risk of drugs is much more harmful for the fetus than the real teratogenic effect of some drugs themselves. Medical doctors and other experts therefore need more education to know the principles and findings of modern human teratology because it may help us to have a better balance between the risk and benefit of drug use during pregnancy.
Lupus 02/2004; 13(9):740-5. DOI:10.1191/0961203303lu1095oa · 2.20 Impact Factor
Available from: medsci.org
International journal of medical sciences 01/2005; DOI:10.7150/ijms.2.100 · 2.00 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.